TY - JOUR
T1 - Flutrimazole 1 % dermal cream in the treatment of dermatomycoses: A multicentre, double-blind, randomized, comparative clinical trial with bifonazole 1 % cream: Efficacy of flutrimazole 1% dermal cream in dermatomycoses
AU - Alomar, A.
AU - Videla, S.
AU - Delgadillo, J.
AU - Gich, I.
AU - Izquierdoh, I.
AU - Forn, J.
AU - Muntañola, A. Alomar
AU - Masoliver, A. Azon
AU - Corominas, A. Ballestero
AU - Montesinos, E. Barberá
AU - Bresca, S. Bassas
AU - Seuma, J. M.Casanoves
AU - Rodellas, A. Castells
AU - Foraster, C. Ferràndiz
AU - Marqués, J. M.García
AU - Alava, J. Gil
AU - Sariola, C. Janes
AU - Llach, E. Llistosella
AU - Cardell, C. Marqués
AU - Tosquets, X. Noguera
AU - Vila, M. Planagumà
AU - Danés, N. Salvatella
AU - Domenjó, I. Vilaltella
AU - Vilaplana, J. Vilaplana
AU - Vila, P. Vives
AU - Sendra, J. M.Vives
AU - Musons, M. Algueró
AU - Satorras, E. Boncompte
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Background: Flutrimazole is a new imidazole derivate. Its antifungal activity has been demonstrated in in vivo and in vitro studies to be comparable to that of clotrimazole and higher than bifonazole. Aim: To compare the efficacy and tol- erability of flutrimazole cream 1% with a reference drug, bifonazole, in the treat-ment of dermatomycoses, eligible for topical treatment exclusively. Methods: A multicentre, double-blind, ramdomized, parallel-group clinical trial was conducted. Patients with clinically and mycologically (KHO and/or culture) diagnosed fungal infection of the skin were included in this study and were randomized into two treatment groups: I % flutrimazole or 1 % bifonazole, applied to the affected area (target lesion) once a day. The principal criterion of efficacy, ‘cure’, was based on clinical and mycological assessment. Results: Four hundred and forty-nine patients were included in the study (228 flutrimazole, 221 bifonazole). intention-to-treat’ analysis of the data showed a difference between the treatments in terms of the rate of cure (clinical and mycological) after 4 weeks: 73% in the flutrimazole group and 65% in the bifonazole group (p = 0.05). From a safety point of view, flutrimazole and bifonazole were well tolerated, and the overall incidence of adverse effects (mainly mild local effects like irritation or burning sensation) was 5%. Conclusions: One percent flutrimazole applied topically once a day in the treatment of fungal infections of the skin presents a better efficacy than bifonazole and a good tolerability. © 1995 S. Karger AG, Basel.
AB - Background: Flutrimazole is a new imidazole derivate. Its antifungal activity has been demonstrated in in vivo and in vitro studies to be comparable to that of clotrimazole and higher than bifonazole. Aim: To compare the efficacy and tol- erability of flutrimazole cream 1% with a reference drug, bifonazole, in the treat-ment of dermatomycoses, eligible for topical treatment exclusively. Methods: A multicentre, double-blind, ramdomized, parallel-group clinical trial was conducted. Patients with clinically and mycologically (KHO and/or culture) diagnosed fungal infection of the skin were included in this study and were randomized into two treatment groups: I % flutrimazole or 1 % bifonazole, applied to the affected area (target lesion) once a day. The principal criterion of efficacy, ‘cure’, was based on clinical and mycological assessment. Results: Four hundred and forty-nine patients were included in the study (228 flutrimazole, 221 bifonazole). intention-to-treat’ analysis of the data showed a difference between the treatments in terms of the rate of cure (clinical and mycological) after 4 weeks: 73% in the flutrimazole group and 65% in the bifonazole group (p = 0.05). From a safety point of view, flutrimazole and bifonazole were well tolerated, and the overall incidence of adverse effects (mainly mild local effects like irritation or burning sensation) was 5%. Conclusions: One percent flutrimazole applied topically once a day in the treatment of fungal infections of the skin presents a better efficacy than bifonazole and a good tolerability. © 1995 S. Karger AG, Basel.
KW - Antifungal therapy
KW - Bifonazole
KW - Dennatomycoses
KW - Flutrimazole
U2 - 10.1159/000246720
DO - 10.1159/000246720
M3 - Article
SN - 1018-8665
VL - 190
SP - 295
EP - 300
JO - Dermatology
JF - Dermatology
IS - 4
ER -